Nutrition
4 min read
December 10, 2022
Vitamin B6 and PMS

Vitamin B6 and PMS

Vitamin B6 has been studied for decades as a supportive intervention for Premenstrual Syndrome, with consistent evidence showing reductions in both psychological and physical symptoms. Clinical trials and meta-analyses suggest that therapeutic doses—well above dietary intake—may be required to achieve meaningful symptom relief.

The effectiveness of Vitamin B6 in the treatment of PMS dates back over 40 years. Results were noted, such as:

  • ‘Significant decreases in all symptoms’ (1)
  • 70% reporting good or partial response’ (2)
  • ‘Improvement in 63% of patients on pyridoxine’ (3)

The dose used within these studies ranged from 40-200mg (with a possible risk of toxicity at 200mg).

Only one patient of the 940 participating in these trials indicated the presence of any side effects that could be attributed to the neuropathy associated with pyridoxine toxicity. (4)

A meta-analysis of nine published trials involving almost 1,000 women with PMS found that vitamin B6 is more effective in reducing PMS symptoms than placebo. (5)

A double-blind, randomized controlled trial in 94 women found that 80 mg pyridoxine taken daily over the course of three cycles was associated with statistically significant reductions in a broad range of PMS symptoms, including:

  • Moodiness
  • Irritability
  • Forgetfulness
  • Bloating
  • Anxiety (6)

Below are my preferred dietary sources of Vitamin B6 per 100g:

  • Liver – 1mg
  • Salmon – 0.9mg
  • Sunflower Seeds – 1.33mg
  • Pistachios – 1.7mg

The recommended daily allowance sits around 1.3mg, which makes an easy target to obtain via food.

However, to achieve the dosage used in the above studies is between 30-153 times higher than the RDA, making it unachievable to obtain through diet alone.

As you can see here, Designs For Health provides 50mg of Vitamin B6 in just one capsule. This is in the form of Vitamin B6 in its most bioavailable form – P5P.

Magnesium and Vitamin B2 are required for the conversion of P5P. The deficiency rates of magnesium make this conversion much harder.

High protein diets or genetic susceptibilities (such as NBPF3) are factors that can increase the need for more Vitamin B6.

Have you ever used B6 for your PMS?

References:

  1. Goei and Abraham, 1983
  2. Brush, 1988
  3. Day, 1979
  4. London RS, et al. 1991
  5. Wyatt KM, et al. BMJ 1999
  6. Kashanian M, et al. 2007

Next news

Are you currently exposed to phthalates on a regular basis? Were you exposed during early developmental stages—for example, through maternal exposure such as a mother working in a hair salon while pregnant? Have you noticed symptom improvement after reducing phthalate exposure?

Higher phthalate levels have been associated with a two-fold increase in the rate of endometriosis. Phthalates are present in almost anything fragranced and are widely used in soft plastics, vinyl, cleaning products, nail polish, and perfumes. As early as 2002, environmental groups reported that over 70% of personal care products contained phthalates. Today, according to the Environmental Protection Agency, more than 470 million pounds of phthalates are produced each year.

Phthalates are now officially recognised as reproductive toxins throughout both the European Union and the United States. Animal studies show that rats given high doses of certain phthalates stopped ovulating altogether. Phthalates reduce oestrogen production by ovarian follicles—oestrogen being one of the primary drivers of follicle growth and egg development in both animals and humans. Suppression of oestrogen by follicle cells would be expected to impair follicle growth, helping explain why women with endometriosis often exhibit significantly higher phthalate levels than those without the condition.

Potential sources of exposure are extensive. Plastics can leach into food, particularly when food is packaged while hot or stored in plastic for long periods. Personal care products are a major contributor, including cosmetics, hair products, lotions, infant care products, medications, medical devices, nail polish, and perfumes.

Vinyl products are another source, such as shower curtains, flooring, wallpapers, blinds, diaper mats, rain gear, inflatable mattresses, school supplies, car interiors, and yoga mats. Additional exposures may come from air fresheners, electronics, plastic jewellery, sex toys, and children’s toys.

Given their prevalence and biological impact, understanding and minimising phthalate exposure is an important consideration in hormone and reproductive health.

Women's Health
6 min read
Phthalates and endometriosis
Phthalates and endometriosis
Commonly found in plastics, fragrances, and personal care products, phthalates can interfere with oestrogen production and reproductive function. Reducing exposure may be a meaningful step in addressing hormone-related symptoms.
February 8, 2022

A defining moment in human health

We are standing at the edge of a defining moment in human history — one that will reshape how health is understood, managed, and lived. Most practitioners won’t see it coming until it’s already here. The pace of change is no longer linear; it’s accelerating at a parabolic rate.

Over the next ten years, healthcare will undergo a larger transformation than it has in the past two hundred. What once took generations to evolve will soon happen within a single career span.

Why the next leap will eclipse the last 200 years

In the 1850s, global life expectancy hovered around 35 to 40 years. In industrial cities such as Manchester, it was recorded as low as 26. Up to 40% of children died before the age of five. Since then, humanity has doubled its average lifespan — one of the greatest achievements in modern history.

But that magnitude of progress will soon appear slow compared to what lies ahead. To understand why, we must look at how medicine has actually evolved — not as a straight line, but as a series of paradigm shifts.

Medicine has never moved in a straight line

Medicine does not evolve gradually. It moves through distinct eras, each defined by its dominant questions, tools, and limitations. Every era solves the problems of its time — and creates the blind spots of the next.

Medicine 1.0: survival through intervention

The age of infection and emergency care (1800s–1950s)

The first modern era of medicine was built around one core mission: survival. Its philosophy was direct and uncompromising — find the problem, cut it out, kill the pathogen. The focus was acute illness, trauma, and infectious disease. Surgery, antibiotics, vaccines, early imaging, and public health measures transformed mortality rates almost overnight.

Breakthroughs such as germ theory, penicillin, antisepsis, and sanitation saved millions of lives. Yet this era had little understanding of long-term health. There was no framework for chronic disease, prevention, or personalisation. Medicine 1.0 was exceptional in emergencies, but largely blind to the slow decline of health over time.

Medicine 2.0: managing disease, not health

The rise of chronic disease frameworks (1950s–2010s)

As life expectancy increased, the medical challenge shifted. Infectious disease gave way to chronic illness. Medicine 2.0 emerged with a new goal: management. Cardiovascular disease, diabetes, cancer, and mental health disorders became the dominant focus.

Pharmaceuticals, specialist referrals, evidence-based medicine, and large clinical trials defined this era. Disease was framed as isolated dysfunction within individual organ systems. While imaging, surgical techniques, and electronic health records advanced rapidly, care became fragmented. Poly-pharmacy increased, symptoms were suppressed rather than resolved, and patients often cycled endlessly through the system.

Medicine 2.0 kept people alive — but rarely helped them thrive.

Medicine 3.0: personalisation, prevention, and patterns

From symptoms to systems (2010s–2025)

The limitations of chronic disease management gave rise to a new way of thinking. Medicine 3.0 reframed health as a dynamic, interconnected system shaped by genetics, environment, lifestyle, and time. The focus shifted toward root causes, prevention, and optimisation.

Functional blood work, genomics, microbiome testing, wearables, and systems biology expanded what was possible. Practitioners began looking for patterns rather than isolated markers. Precision nutrition and functional reference ranges replaced one-size-fits-all recommendations.

Yet this era introduced new challenges. Data became abundant but scattered. Interpretation demanded high cognitive load. Standards varied widely, access remained inconsistent, and outcomes depended heavily on practitioner experience. While powerful, Medicine 3.0 was difficult to scale.

Many believe this is the peak of modern healthcare.

Why medicine 3.0 is not the end point

Despite its advances, Medicine 3.0 still relies on humans to manually integrate overwhelming amounts of data, make predictions, and adjust protocols over time. It improved insight — but not intelligence. It offered tools — but not true systems.

The next era changes that entirely.

Medicine 4.0: intelligence, automation, and decentralised health

Predictive, adaptive, and continuously evolving care (2025–2040+)

Medicine 4.0 represents a fundamental shift in how health is defined and managed. Health becomes a continuously evolving dataset, updated in real time across all stages of life. The focus moves from reaction to prediction, from static plans to adaptive systems, from intervention to self-correction.

Artificial intelligence, machine learning, digital twins, predictive analytics platforms, continuous multi-biomarker wearables, synthetic biology, and autonomous medical systems will allow health trajectories to be forecast before disease manifests. Diagnostics will become ambient. Treatment will adapt dynamically. Biology itself becomes increasingly programmable.

But this transformation comes with real challenges — data privacy, equity, over-reliance on technology, loss of human connection, and the risk of eroding individual agency. Intelligence must be guided, not blindly trusted.

Building the infrastructure for medicine 4.0

This is where MyHealthPrac enters — not as a response to Medicine 4.0, but as an early foundation for it.

MyHealthPrac is a decentralised health management system designed to translate complexity into clarity. Built on over a decade of research, line-by-line journal reviews, and clinically informed logic, it transforms vast amounts of health data into actionable, root-cause solutions. Hard-coded algorithms, pattern recognition, and predictive frameworks allow practitioners to move beyond interpretation and into intelligence.

This is not theory. It is not a distant vision.

Not the future of health — the next standard

Medicine 4.0 is not coming someday. It is arriving now. And the systems built today will determine whether this new era empowers practitioners and individuals — or overwhelms them.

MyHealthPrac is being built to lead that transition.

Philosophy
6 min read
The 4 ages of medicine and the one we haven’t met yet
The 4 ages of medicine and the one we haven’t met yet
Medicine is entering a new era. From infection control to intelligent, predictive systems, this article traces the evolution of healthcare — and explains why Medicine 4.0 will transform how the world manages health.
August 5, 2025

Below are alternative methods which have been studied for their efficacy and effectiveness in combating postpartum depression.

Saffron

A double-blind, randomised, placebo-controlled trial was conducted on 60 new mothers diagnosed with PPD. After 8 weeks, results showed that the saffron group experienced a 96% remission rate for postpartum depression from just 15-mg Saffron per day, more than double the remission rate of placebo group ‘Researchers concluded that saffron can have a safe and significant mood-elevating impact for those suffering from postpartum depression who want to safely breast-feed their newborns’ (8)

When compared with antidepressant medications, saffron has been found to have similar efficacy – without the side effects.

Folate

In placebo-controlled trials, folate has been used as an adjunctive treatment to fluoxetine. Findings indicated significantly greater improvement in the folate group, a difference most pronounced in women (14)

94% of women who received fluoxetine, with the addition of folate 500 mcg per day, were treatment responders, compared with 61% of those who received fluoxetine and placebo

It is recommended that women of reproductive age consume 0.4–1 mg folate daily to reduce the risk of neural tube birth defects.

Exercise

Exercise is integral to optimal health in pregnancy, as well as in the prevention of heart disease, obesity, and diabetes, along with other comorbid diseases. Regular physical activity (after selectively auditing through 216 studies) during pregnancy, pregnancy, and puerperium, or in the postnatal period itself as compared to inactivity, was found to reduce the risk of developing depression in pregnant women and after the birth of a child (6)

Massage

A meta-analysis of 17 RCTs of massage therapy in depressed people concluded that massage therapy is significantly associated with reduced depressive symptoms (11), decreased urinary levels of cortisol (12); and increased urinary levels of serotonin and dopamine (13)

The purpose of this post is to raise awareness and display the vast array of possible paths one could take in supporting their own mental well-being when combatting PPD.

Infant Massages

Infant massage improves mother-infant interaction for mothers with postnatal depression (7)

Seafood

In a large Danish prospective cohort study of more than 54,000 women, participants who were in the lowest quartile of self-reported fish intake during pregnancy were at increased risk of being treated for depression with an antidepressant up to 1-year postnatally (9). Rather than extrapolating this solely to benefits Omega-3, it is important to take into account that sociodemographic characteristics not only influence food availability in house-hold diets but also emotional statue

Bright Light Therapy

In participants who received at least three weeks of bright light therapy each morning for 1-hr had improvements in their depression scores by a mean of 49%; among participants who completed at least 5 weeks, scores improved by 59% (10)

Caveats in this field of research are that the study pools are low most likely due to the ‘cost vs return’ of investing into studies in this sector

References:

  1. J Midwifery Womens Health. 2013 Nov-Dec; 58(6): 643–653.
  2. Lindah l V, Pearson J L, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health 2005;8:77–87.
  3. Phytomedicine. 2017 Dec 1;36:145-152. doi: 10.1016/j.phymed.2017.10.005. Epub 2017 Oct 7.
  4. Clin Obstet Gynecol. 2009 Sep; 52(3):456-68.
  5. Acta Obstet Gynecol Scand. 2001 Mar; 80(3):251-5.
  6. Medicina (Kaunas). 2019 Sep 2 ;55(9). Epub 2019 Sep 2. PMID: 31480778
  7. J Affect Disord. 2001 Mar;63(1-3):201-7. PMID: 11246096
  8. J Integr Med. 2013 Nov;11(6):377-83. doi: 10.3736/jintegrmed2013056.
  9. Strom M, Mortensen EL, Halldorsson TI, et al. Fish and long-chain n-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort. Am J Clin Nutr 2009; 90:149–55.
  10. Oren DA, Wisner KL, Spinelli M, et al. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry 2002;159:666–9.
  11. Hou WH, Chiang PT, Hsu TY, et al. Treatment effects of massage therapy in depressed people: a meta-analysis. J Clin
    Psychiatry 2010;71:894–901.
  12. Field T, Diego M, Hernandez-Reif M, et al. Pregnancy massage reduces prematurity, low birthweight and postpartum depression. Infant Behav Dev 2009;32:454–60.
  13. Field T, Diego MA, Hernandez-Reif M, et al. Massage therapy effects on depressed pregnant women. J Psychosom Obstet Gynaecol 2004;25:115–22.
  14. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000;60:121-30.
  15. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S 61S.
  16. Roder C, Schaefer M, Leucht S. Meta analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John’s Wort [in German]. Fortschr Neurol Psychiatr 2004;72:330–43.

Women's Health
6 min read
Combatting postpartum depression
Combatting postpartum depression
Evidence suggests that nutrients, movement, touch, light exposure, and lifestyle-based interventions—such as saffron, folate, exercise, massage, seafood intake, infant massage, and bright light therapy—may meaningfully reduce PPD symptoms and expand the range of supportive options available to new mothers.
December 20, 2022
Clarity, confidence, and real results start with one conversation. Let’s map your next chapter — together.